Magdi Ghali, MD
Interventional Cardiology · West Des Moines, IANPI 1073595112
Payments from drug & device makers
Across 966 payments — averaging $551.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$336K
- Penumbra, Inc.$86K
- Cardiovascular Systems Inc.$62K
- AstraZeneca$13K
- E.r. Squibb & Sons, L.L.C.$10K
- Pfizer$9K
- plus $17K from 29 others
Across 1 payment — averaging $21.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abiomed$21
What the payments were for
- Consulting fees$1,2002%
- Speaking & faculty fees$38,89861%
- Travel & lodging$2,9875%
- Food & beverage$21,03033%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 258 | $335,731 |
| Penumbra, Inc. | 40 | $86,374 |
| Cardiovascular Systems Inc. | 99 | $62,192 |
| AstraZeneca | 21 | $12,586 |
| E.r. Squibb & Sons, L.L.C. | 35 | $9,590 |
| Pfizer | 29 | $8,708 |
| Abbott | 138 | $5,487 |
| Abiomed | 93 | $2,642 |
| Shockwave Medical, Inc | 56 | $2,049 |
| Boston Scientific | 35 | $1,280 |
| Silk Road Medical, Inc. | 5 | $782 |
| Philips North America LLC | 43 | $685 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 33 | $597 |
| Teleflex LLC | 10 | $498 |
| Impulse Dynamics (USA) Inc. | 4 | $393 |
| Cardiva Medical, Inc. | 11 | $325 |
| Amgen | 5 | $300 |
| Novartis | 11 | $245 |
| Heartflow, Inc. | 6 | $221 |
| Chiesi USA, Inc. | 4 | $184 |
| Recor Medical Inc | 2 | $180 |
| Terumo Medical Corporation | 7 | $157 |
| Biotronik Inc. | 2 | $156 |
| Asahi Intecc USA, Inc. | 1 | $147 |
| Portola Pharmaceuticals, LLC | 1 | $132 |
| Inari Medical, Inc. | 3 | $128 |
| Boehringer Ingelheim | 3 | $123 |
| Biocompatibles, Inc. | 1 | $110 |
| Johnson & Johnson | 3 | $104 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $60 |
| Novo Nordisk | 2 | $31 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Cook Medical LLC | 1 | $24 |
| Angiodynamics, Inc. | 1 | $23 |
| Edwards Lifesciences | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$15,985
- BRILINTA$11,828
- Coronary Orbital Atherectomy System$5,850
- Diamondback Coronary$4,236
- Indigo System$3,581
- OPTIS$1,890
- Impella$1,584
- MO.MA ULTRA$996
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$894
- OPTIMIZER$710
- ENROUTE Transcarotid Neuroprotection System$694
- ENROUTE Transcarotid Stent System$694
- ENHANCE Transcarotid Peripheral Access Kit$694
- ENROUTE 0.014 Guidewire$694
- FARXIGA$391
- VYNDAQEL$335
- Vascular Lithotripsy$333
- ANDEXXA$242
- Indigo$209
- Ultreon$177
How this compares
$532,287 in reported general payments places this provider in the 95th percentile of 64 interventional cardiology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 228 | $180,454 |
| BrilintaTicagrelor | 52 | $41,981 |
| Repatha SureclickEvolocumab | 14 | $8,837 |
| Bisoprolol Fumarate | 301 | $5,454 |
| Ranolazine ErRanolazine | 32 | $2,718 |
| Atorvastatin Calcium | 320 | $2,364 |
| Prasugrel Hcl | 54 | $2,004 |
| Nebivolol Hcl | 22 | $1,840 |
| Metoprolol Succinate | 159 | $1,731 |
| Rosuvastatin Calcium | 184 | $1,520 |
| Pitavastatin Calcium | 15 | $1,477 |
| ClopidogrelClopidogrel Bisulfate | 197 | $1,443 |
| Ezetimibe | 36 | $1,025 |
| Bisoprolol-HydrochlorothiazideBisoprolol/Hydrochlorothiazide | 51 | $815 |
| Amlodipine Besylate | 162 | $675 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $8,708 | $180,454228 claims |
| AstraZenecaBrilinta | $12,586 | $41,98152 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 64 interventional cardiology providers in Iowa.
Other interventional cardiology in West Des Moines
- James LovellWest Des Moines$245K
- Mark TannenbaumWest Des Moines$232K
- Michael FraizerWest Des Moines$1K
- Liberato IannoneWest Des Moines$1K
- Nicolas ShammasDavenport$4.8M
- Phillip HorwitzIowa City$2M
- Atul ChawlaDes Moines$485K
- David McAllisterDes Moines$149K
- Daniel ShivapourDes Moines$135K
- Eric DippelDavenport$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.